CRL · 8-K · 20260805PR000115

Products and Technology

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 31 · Surprise 42

Charles River joined Eli Lilly’s TuneLab AI/ML platform, contributing non-clinical testing expertise to drug-discovery optimization and R&D modernization. It collaborated with Arovella Therapeutics to provide in vitro Next Generation Sequencing (NGS) services, an offering added through the PathoQuest acquisition, to support alternative cancer-treatment development. The company also introduced an AI-enabled enhanced digital pathology solution with an end-to-end workflow designed to improve study turnaround times and pathologist efficiency.